Elenagen, a novel DNA immunotherapy for the deadliest form of ovarian cancer, delays disease progression
SCIENMAG: Medicine & Health
FEBRUARY 22, 2024
BOSTON, February 22, 2024: CureLab Oncology, a clinical-stage, pre-IPO biotech company, announced that its novel biological agent, Elenagen, has been shown to significantly enhance standard chemotherapy and provides clinical benefits for the patients with the deadliest form ovarian cancer. Credit: CureLab Oncology Inc.
Let's personalize your content